Decoding Q1: Insights on XENE, DCTH, RNXT, FENC
Last month, we wrote about Xenon Pharmaceuticals (Nasdaq: XENE) and Delcath Systems (Nasdaq: DCTH) as two of our favorite names in this volatile biotech…
Coverage
Blog
Latest research notes and coverage from the editorial archive.
Protara’s Small Sample, Big Potential & Rezolute’s Rebound
We have received numerous questions regarding the performance, or lack thereof, of Protara Therapeutics’ (Nasdaq: TARA) stock following their recent release of updated six-…
Franchise Building: Xenon & Delcath
Over the past several months, investing in biotech has felt like catching a falling knife. At the sector level, the departure of key personnel…
Likeness: Bright Minds, Delcath, Novocure, Trisalus…RenovoRx?
During bleak times like this in biotech, it is helpful to remember why we invest in this space. The potential for moonshot returns is…
Near-Term Data, Plump Balance Sheets & Calling It: Nektar, Ventyx & Xenon
We have written previously about Nektar Therapeutics (Nasdaq: NKTR) as a chronically out-of-favor name despite having a near-term data readout and a plump treasury.…
Tailwinds & Tardiness: FDA, Cybin & Entera
The data supporting the potential benefit of psychedelics in the management of psychiatric disorders continues to grow after Monday’s news from GH Research (Nasdaq: GHRS)…
Trading Sideways: Better Days Ahead For Two Data-Rich Stories?
Last week, Ventyx Biosciences (Nasdaq: VTYX) provided a pipeline update. There were no surprises in the update, with the company restating the timing of…
FDA’s Imminent BMD Decision
This month, FDA is expected to make a qualification decision for total hip bone mineral density (BMD) as an approvable surrogate endpoint for future…
Soleno’s PDUFA Push & Satellos’ Ambitious DMD Plans
In late November, Soleno Therapeutics (Nasdaq: SLNO) announced that FDA had pushed the PDUFA date for their DCCR / Prader-Willi Syndrome NDA by three…
Protara Inserts Itself Into NMIBC Discussion
Last week, Protara Therapeutics (Nasdaq: TARA) reported interim data from their ongoing ADVANCE-2 study with TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). …